Evelo Biosciences, Inc. (EVLO)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
At close: 03:47PM EDT
| Previous close | 0.0500 |
| Open | 0.0495 |
| Bid | 0.0000 x 2900 |
| Ask | 0.0000 x 1000 |
| Day's range | 0.0360 - 0.0495 |
| 52-week range | 0.0280 - 13.9300 |
| Volume | |
| Avg. volume | 38,433 |
| Market cap | 939,648 |
| Beta (5Y monthly) | 2.03 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
- Primary endpoint was not achieved – - Company exploring strategic alternatives and partnering opportunities for EDP1815 and its SINTAX platform - CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) (“Evelo” or the “Company”), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced top-line results from its Phase 2 clinical study wit
© 2024 Yahoo. All rights reserved.